BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De Sells 46,896 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 46,896 shares of BioLife Solutions stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the completion of the transaction, the chief executive officer now owns 414,958 shares of the company’s stock, valued at $9,722,465.94. This trade represents a 10.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

BioLife Solutions Stock Up 2.1 %

Shares of NASDAQ BLFS opened at $27.69 on Thursday. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92. The firm has a 50-day moving average price of $25.91 and a 200 day moving average price of $24.27.

Wall Street Analyst Weigh In

Several research firms have commented on BLFS. Northland Securities boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday. TD Cowen raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reissued a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.43.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently added to or reduced their stakes in BLFS. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions in the 3rd quarter valued at approximately $28,000. Quest Partners LLC acquired a new position in BioLife Solutions in the 3rd quarter valued at about $57,000. GAMMA Investing LLC boosted its stake in shares of BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the second quarter valued at approximately $122,000. Finally, Arizona State Retirement System acquired a new stake in BioLife Solutions during the second quarter worth approximately $217,000. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.